Sign In
Buy DXCM
$76.35
+1.39 (+1.85%)
At Close: Jul 13, 2026
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
04:45pm, Monday, 13'th Jul 2026
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Gluc
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
09:00am, Thursday, 09'th Jul 2026
[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
08:30am, Thursday, 09'th Jul 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will
Here's Why DexCom (DXCM) is a Strong Growth Stock
10:45am, Wednesday, 08'th Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
03:36pm, Monday, 06'th Jul 2026
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performa
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
12:27pm, Friday, 03'rd Jul 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
DexCom: The Growth Thesis Still Needs To Be Proven
02:10am, Thursday, 02'nd Jul 2026
DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains u
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
09:36am, Friday, 26'th Jun 2026
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
10:31am, Wednesday, 24'th Jun 2026
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.
Dexcom Further Advances Vision of Glucose Biosensing for All
09:00am, Tuesday, 23'rd Jun 2026
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucos
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
08:45am, Saturday, 20'th Jun 2026
The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo
Living Longer Is Big Business. These Stocks Will Benefit.
02:14pm, Thursday, 18'th Jun 2026
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
3 Stocks Doing the Heavy Lifting in Healthcare's Rebound
09:31am, Thursday, 18'th Jun 2026
Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks ha
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
10:56am, Tuesday, 16'th Jun 2026
DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.
